Yu Kataoka1, Stephen J Nicholls2, Jordan Andrews3, Kiyoko Uno4, Samir R Kapadia5, E Murat Tuzcu5, Steven E Nissen5, Rishi Puri5,6. 1. Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Center, Suita, Japan. 2. Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Melbourne, Australia. 3. South Australian Health & Medical Research Institute, University of Adelaide, Adelaide, Australia. 4. Teikyo Academic Research Center, Teikyo University, Tokyo, Japan. 5. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA. 6. Cleveland Clinic Coordinating Center for Clinical Research, Cleveland, Ohio, USA.
Abstract
Background: While metformin is recommended as a first-line cardioprotective therapy for type 2 diabetic patients, whether it exerts direct effects on atherosclerotic plaque remains uncertain. The current study characterized coronary plaque microstructures in type 2 diabetic patients who received metformin. Methods: We retrospectively analyzed 409 non-culprit lipid plaques in 313 type 2 diabetic patients with coronary artery disease (CAD) by using frequency-domain optical coherence tomography (FD-OCT) imaging. FD-OCT derived plaque microstructures were compared in patients stratified according to metformin use. Results: A proportion of 38.6% of study subjects received metformin. Patients receiving metformin more likely exhibited a history of hypertension (79.3% vs. 67.1%, P=0.03) and metabolic syndrome (52.8% vs. 36.4%, P=0.01). On FD-OCT imaging, the prevalence of lipid plaque was lower in the metformin group (66.2% vs. 77.9%, P=0.03). Furthermore, the metformin group demonstrated plaques with a smaller lipid arc (median: 168.7° vs. 208.5°, P=0.008), shorter longitudinal length (media: 5.1 vs. 9.1 mm, P=0.04), and a lower frequency of cholesterol crystal (3.9% vs. 18.2%, P=0.01) and spotty calcification (3.9% vs. 34.8%, P=0.008). These differences remained significant after adjusting for clinical characteristics and glycemic control. However, in patients who received insulin, the favourable effect of metformin on lipid arc was not observed (insulin user: P=0.87; insulin non-user: P=0.009; P value for interaction between two groups, P=0.02). Conclusions: Metformin use was associated with a lower prevalence of vulnerable plaque features in type 2 diabetic patients with CAD, especially insulin non-user. These findings suggest the potential of metformin to exert direct plaque stabilization effects in type 2 diabetic subjects. 2022 Cardiovascular Diagnosis and Therapy. All rights reserved.
Background: While metformin is recommended as a first-line cardioprotective therapy for type 2 diabetic patients, whether it exerts direct effects on atherosclerotic plaque remains uncertain. The current study characterized coronary plaque microstructures in type 2 diabetic patients who received metformin. Methods: We retrospectively analyzed 409 non-culprit lipid plaques in 313 type 2 diabetic patients with coronary artery disease (CAD) by using frequency-domain optical coherence tomography (FD-OCT) imaging. FD-OCT derived plaque microstructures were compared in patients stratified according to metformin use. Results: A proportion of 38.6% of study subjects received metformin. Patients receiving metformin more likely exhibited a history of hypertension (79.3% vs. 67.1%, P=0.03) and metabolic syndrome (52.8% vs. 36.4%, P=0.01). On FD-OCT imaging, the prevalence of lipid plaque was lower in the metformin group (66.2% vs. 77.9%, P=0.03). Furthermore, the metformin group demonstrated plaques with a smaller lipid arc (median: 168.7° vs. 208.5°, P=0.008), shorter longitudinal length (media: 5.1 vs. 9.1 mm, P=0.04), and a lower frequency of cholesterol crystal (3.9% vs. 18.2%, P=0.01) and spotty calcification (3.9% vs. 34.8%, P=0.008). These differences remained significant after adjusting for clinical characteristics and glycemic control. However, in patients who received insulin, the favourable effect of metformin on lipid arc was not observed (insulin user: P=0.87; insulin non-user: P=0.009; P value for interaction between two groups, P=0.02). Conclusions: Metformin use was associated with a lower prevalence of vulnerable plaque features in type 2 diabetic patients with CAD, especially insulin non-user. These findings suggest the potential of metformin to exert direct plaque stabilization effects in type 2 diabetic subjects. 2022 Cardiovascular Diagnosis and Therapy. All rights reserved.
Authors: George S Abela; Kusai Aziz; Ameeth Vedre; Dorothy R Pathak; John D Talbott; Joyce Dejong Journal: Am J Cardiol Date: 2009-02-07 Impact factor: 2.778
Authors: Yu Kataoka; Muhammad Hammadah; Rishi Puri; Bhanu Duggal; Kiyoko Uno; Samir R Kapadia; E Murat Tuzcu; Steven E Nissen; Stephen J Nicholls Journal: Atherosclerosis Date: 2015-08-08 Impact factor: 5.162
Authors: J R Rumble; M E Cooper; T Soulis; A Cox; L Wu; S Youssef; M Jasik; G Jerums; R E Gilbert Journal: J Clin Invest Date: 1997-03-01 Impact factor: 14.808
Authors: Yu Kataoka; Rishi Puri; Muhammad Hammadah; Bhanu Duggal; Kiyoko Uno; Samir R Kapadia; E Murat Tuzcu; Steven E Nissen; Stephen J Nicholls Journal: Cardiovasc Diagn Ther Date: 2014-12
Authors: Peter Duewell; Hajime Kono; Katey J Rayner; Cherilyn M Sirois; Gregory Vladimer; Franz G Bauernfeind; George S Abela; Luigi Franchi; Gabriel Nuñez; Max Schnurr; Terje Espevik; Egil Lien; Katherine A Fitzgerald; Kenneth L Rock; Kathryn J Moore; Samuel D Wright; Veit Hornung; Eicke Latz Journal: Nature Date: 2010-04-29 Impact factor: 49.962
Authors: Stephen J Nicholls; E Murat Tuzcu; Srinivasa Kalidindi; Kathy Wolski; Keon-W Moon; Ilke Sipahi; Paul Schoenhagen; Steven E Nissen Journal: J Am Coll Cardiol Date: 2008-07-22 Impact factor: 24.094